Viewing Study NCT00261612


Ignite Creation Date: 2025-12-26 @ 10:18 PM
Ignite Modification Date: 2026-02-05 @ 9:52 PM
Study NCT ID: NCT00261612
Status: UNKNOWN
Last Update Posted: 2006-10-18
First Post: 2005-12-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Sponsor: Medical University of Vienna
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, Mantle-Cell View
Keywords:

Keywords

Keyword Brief Keyword Text View
None relapsed or chemotherapy-refractory disease View